Extend your product line easily to whole new markets using the newly designed capsule that enables contents to be orally administered by simply sprinkling the contents into soft food. What's more, Coni-Snap® sprinkle is far easier to open.
The main issue when using standard hard capsules is their strong locking mechanism requiring sufficient grip strength and dexterity to reopen the capsule. Coni-Snap® sprinkle capsules have an innovative closure that needs less force to open so it can be opened much easier and safer. Based on the trusted Coni-Snap® design, it can be filled on the same machines as traditional capsules but will remain in place during packaging and transportation.
Consumer tests have confirmed that Coni-Snap® sprinkle capsules are easier to open than traditional capsules. Including parents, caregivers, and elderly patients, 81% of participants described the design as easy or very easy to open.
Reformulating a product for specific patient groups can be challenging and time consuming. Capsugel's multiparticulate formulation options simplify drug design for optimized dosage forms for bioavailability enhancement, modified release, taste-masking and other functionality. And Coni-Snap sprinkle offers an easy open, cost-effective design for delivery of multiparticulate formulations.
Capsugel has a full range of multiparticulate (MP) formulation technologies that are increasingly utilized in drug delivery for specialized populations. MP technologies can be effectively used to address a range of formulation challenges including bioavailability enhancement, modified release, taste-masking, and combination products. Our range of processing technologies include spray-layered multiparticulates, extruded beads and mini-tablets. New lipid multiparticulate technology, produced by proprietary melt-spray-congeal processing, can be used to encapsulate active ingredients in a range of lipids to tailor functionality.
Consumer tests have confirmed that Coni-Snap sprinkle capsules are easier to open than traditional capsules. Including parents, caregivers, and elderly patients, 81% of participants described the design as easy or very easy to open.
Evaluation of easiness to open. Product was evaluated by 37 participants in three panels including parents of young children and elderly (non-impaired) people over 80.
Drug product development is traditionally being done on a single compound in patients with a single disease or at least strictly randomized and surveyed. This often misses the "real patients" and major user group to which 70 % in volume of our drugs are prescribed to - the patients beyond 65 years. This webinar draws a basic picture on the real older patients and their needs in complex drug therapy and discuss how this translates into advanced product development and design.